—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Rhythm Pharmaceuticals Inc (RYTM) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RYTM, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in US: −2.1% week · −2.2% month · +3.3% quarter · +16.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 1.11 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How RYTM has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.11 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Rhythm Pharmaceuticals Inc moved 1.11% on average · correlation 0.22 · higher than 90% of US names
  • Beta, last 3 months 1.27 about the same as over the year
  • On the 10 worst bond days −1.28% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.07% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against RYTM on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Rhythm Pharmaceuticals Inc

RYTM in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Rhythm Pharmaceuticals develops treatments for rare genetic forms of obesity linked to faults in the melanocortin-4 receptor pathway that controls hunger. Its approved drug, setmelanotide, treats several of these inherited conditions, and it is testing further MC4R-pathway compounds, including an oral pill and a longer-acting injectable, in patients with related genetic and hypothalamic obesities. It is based in Boston and sells directly to patients diagnosed with these rare conditions rather than the broader obesity market.
Where it sits in the stack
Rhythm sits outside our index build; it belongs to the healthcare and biotechnology sleeve of the diary's universe, alongside other rare-disease drug developers rather than the AI-infrastructure names our indices track.
Who it is priced against
The diary has not set a peer group for it; the comparison the market draws is with Zealand Pharma, another company developing therapies for rare metabolic and obesity-linked conditions.
Why Closelooknet tracks it
It carries no index seat and no Closelooknet score, and the diary has not quoted it in any edition; coverage here rests only on its chart reading.
What the diary watches
Whether trial results for the newer MC4R compounds widen the eligible patient population beyond the rare conditions setmelanotide already treats.

Rhythm Pharmaceuticals Inc (RYTM) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 39/100 composite (momentum 37, quality 21, valuation 6) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What RYTM pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +6.5% in FY2025 67 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Rhythm Pharmaceuticals Inc (RYTM)?

Rhythm Pharmaceuticals Inc trades as RYTM on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is RYTM in a Closelooknet index?

Not currently — Rhythm Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is Rhythm Pharmaceuticals Inc's Closelooknet composite score?

39 out of 100, with momentum 37, quality 21 and valuation 6 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does RYTM trade against its moving averages?

Mixed moving-average stack: Trades -13.5% vs the 50-day and -8% vs the 200-day average, 25.7% below the 52-week high and +21.8% off the 52-week low; a golden cross printed 50 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Rhythm Pharmaceuticals Inc compare with its peers?

Against its peer group (Biotechnology · US), Rhythm Pharmaceuticals Inc (RYTM) sits 25.7% below its 52-week high, 13.5% below its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to RYTM in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Rhythm Pharmaceuticals Inc trade when bond yields rise?

Over the past year Rhythm Pharmaceuticals Inc had a beta of 1.11 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 90% of US names. On the 10 sessions in which long bonds fell most it moved −1.28% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Rhythm Pharmaceuticals Inc do?

Rhythm Pharmaceuticals develops treatments for rare genetic forms of obesity linked to faults in the melanocortin-4 receptor pathway that controls hunger. Its approved drug, setmelanotide, treats several of these inherited conditions, and it is testing further MC4R-pathway compounds, including an oral pill and a longer-acting injectable, in patients with related genetic and hypothalamic obesities. It is based in Boston and sells directly to patients diagnosed with these rare conditions rather than the broader obesity market. The diary has not set a peer group for it; the comparison the market draws is with Zealand Pharma, another company developing therapies for rare metabolic and obesity-linked conditions.

Where does Rhythm Pharmaceuticals Inc sit in the AI build-out?

Rhythm sits outside our index build; it belongs to the healthcare and biotechnology sleeve of the diary's universe, alongside other rare-disease drug developers rather than the AI-infrastructure names our indices track. It carries no index seat and no Closelooknet score, and the diary has not quoted it in any edition; coverage here rests only on its chart reading.

Does Rhythm Pharmaceuticals Inc pay a dividend?

No cash distribution shows in Rhythm Pharmaceuticals Inc’s price series over the last three years. The share count rose 6.5% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for RYTM, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.